In Phase A, participants will obtain various doses and schedules of oral ABBV-744 tablet to establish Protected dosing routine. Additional individuals are going to be enrolled in the determined monotherapy dosign program. In Segment B, contributors will receive oral ruxolitinib and ABBV-744 might be given as "include-on" therapy. In Section https://nielsonl777alw9.wikiadvocate.com/user